Author + information
- Received April 5, 2017
- Revision received May 21, 2017
- Accepted June 1, 2017
- Published online October 30, 2017.
- Jose R. Garcia, MSa,
- Peter F. Campbell, MDb,
- Gautam Kumar, MBBSc,d,
- Jonathan J. Langberg, MDc,
- Liliana Cesar, DVMe,
- Lanfang Wang, MSc,
- Andrés J. García, PhDa and
- Rebecca D. Levit, MDc,∗ ()
- aWoodruff School of Mechanical Engineering, Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia
- bInnovatië LifeSciences, Santa Clara, California
- cDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
- dDivision of Cardiology, Atlanta VA Medical Center, Atlanta, Georgia
- eT3 Labs-Translational, Testing and Training Laboratories, Inc., Atlanta, Georgia
- ↵∗Address for correspondence:
Dr. Rebecca D. Levit, Division of Cardiology, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle, Woodruff Memorial Building, Room 319, Atlanta, Georgia 30322.
• The pericardial space is an unexploited anatomic location for hydrogel delivery.
• Hydrogels can be delivered to the pericardial space in a localized, minimally invasive manner, without detectable hemodynamic effects.
• Pericardial hydrogel delivery is a new strategy to direct therapeutics to the heart with reduced systemic delivery and off-target effects.
Biomaterials are a new treatment strategy for cardiovascular diseases but are difficult to deliver to the heart in a safe, precise, and translatable way. We developed a method to deliver hydrogels to the epicardium through the pericardial space. Our device creates a temporary compartment for hydrogel delivery and gelation using anatomic structures. The method minimizes risk to patients from embolization, thrombotic occlusion, and arrhythmia. In pigs there were no clinically relevant acute or subacute adverse effects from pericardial hydrogel delivery, making this a translatable strategy to deliver biomaterials to the heart.
Dr. Campbell and Dr. Levit are listed as inventors on a patent application filed by Emory University on technology related to the delivery device. Dr. Levit is a principal in a startup company, CorAmi LLC, which seeks to commercialize this technology but as of yet has no investment, revenue, or intellectual property. Funded by Coulter Translational Research Partnership, Georgia Research Alliance. All authors have reported that they have no relationships relevant to the contents of this paper to disclose.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received April 5, 2017.
- Revision received May 21, 2017.
- Accepted June 1, 2017.
- 2017 The Authors